CLLS · Cellectis S.A.
$3.05
-0.13 (-4.09%)
At close · Aug 14
Market Cap
$307.13M
Shares
100.70M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.05
Open$3.15
Day$3.05–3.15
52W close$2.57–5.35
Avg vol 30d17K
Short int296K · 0.3% float · 22.0d
Short vol46%
Last earningsJun 30, 2025
DataJan 2020–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bearish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
+4%
above
RSI (14)
57
neutral
MACD trend
Positive
52-week position
17%
mid-range
Momentum
relative strength
1-month return
+16%
trailing
6-month return
−23%
trailing
YTD return
−37%
this year
Relative strength
−37%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-19% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.29% of float · ▲ +2.2% MoM · 22.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
+4%
Bullish
RSI (14)
57
Neutral
MACD trend
Positive
Bullish
52-week position
17%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
-19% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.29% of float · ▲ +2.2% MoM · 22.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
26 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $3 · 17%
Range high $5
vs 200-day avg -18%
vs 50-day avg +4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLLS
this stock
Cellectis S.A.
|
$307.13M | -37.0% | — | — | 0.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLLS | +7.6% | +16.0% | -23.0% | +10.9% | -37.0% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +7.2% | +11.5% | -36.8% | +7.0% | -50.8% |
Key facts
CIK
1627281
CUSIP
15117K103
13F (30d)
25 filings
25 filers
Visit website
Investor relations